These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26189257)

  • 1. Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays.
    Fan R; Huang W; Luo B; Zhang QM; Xiao SW; Xie XX
    Eur J Gynaecol Oncol; 2015; 36(3):298-303. PubMed ID: 26189257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.
    Tammela J; Uenaka A; Ono T; Noguchi Y; Jungbluth AA; Mhawech-Fauceglia P; Qian F; Schneider S; Sharma S; Driscoll D; Lele S; Old LJ; Nakayama E; Odunsi K
    Int J Oncol; 2006 Oct; 29(4):903-10. PubMed ID: 16964386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.
    Luo B; Yun X; Fan R; Lin YD; He SJ; Zhang QM; Mo FR; Chen F; Xiao SW; Xie XX
    Int J Clin Exp Pathol; 2013; 6(12):2835-45. PubMed ID: 24294369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma.
    Luo B; Yun X; Li J; Fan R; Guo WW; Liu C; Lin YD; Ge YY; Zeng X; Bi SQ; Nong WX; Zhang QM; Xie XX
    Curr Med Sci; 2020 Aug; 40(4):719-728. PubMed ID: 32862383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues.
    Fu J; Yingying Ge ; Qingmei Zhang ; Lin Y; Liu C; Nong W; Luo X; Xiao S; Xie X; Luo B
    J Healthc Eng; 2022; 2022():7052830. PubMed ID: 35463688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.
    Li X; Yan J; Fan R; Luo B; Zhang Q; Lin Y; Zhou S; Luo G; Xie X; Xiao S
    Oncol Lett; 2017 May; 13(5):3080-3086. PubMed ID: 28529561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.
    Ono T; Kurashige T; Harada N; Noguchi Y; Saika T; Niikawa N; Aoe M; Nakamura S; Higashi T; Hiraki A; Wada H; Kumon H; Old LJ; Nakayama E
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3282-7. PubMed ID: 11248070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.
    Fu J; Luo B; Guo WW; Zhang QM; Shi L; Hu QP; Chen F; Xiao SW; Xie XX
    Int J Clin Exp Pathol; 2015; 8(7):7786-97. PubMed ID: 26339343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells.
    Cen YH; Guo WW; Luo B; Lin YD; Zhang QM; Zhou SF; Luo GR; Xiao SW; Xie XX
    Cell Biol Int; 2012 Oct; 36(10):917-22. PubMed ID: 22651134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
    Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
    Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
    Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
    Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
    Whynott RM; Manahan P; Geisler JP
    Eur J Gynaecol Oncol; 2016; 37(2):164-6. PubMed ID: 27172738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG, CD9, CCND2 and CDCA3: a bioinformatic analysis combine with RNAi and oligonucleotide microarray.
    Hu Q; Fu J; Luo B; Huang M; Guo W; Lin Y; Xie X; Xiao S
    Oncol Rep; 2015 Apr; 33(4):1965-75. PubMed ID: 25673160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.
    Lin L; Nong W; Luo B; Ge Y; Zeng X; Li F; Fan R; Zhang Q; Xie X
    Immun Inflamm Dis; 2021 Dec; 9(4):1759-1770. PubMed ID: 34528758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells.
    Okumura H; Noguchi Y; Uenaka A; Aji T; Ono T; Nakagawa K; Aoe M; Shimizu N; Nakayama E
    Microbiol Immunol; 2005; 49(11):1009-16. PubMed ID: 16301813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.